Faculty Spotlight: Michael Chaglasian, OD, FAAO

For over three decades, Michael Chaglasian, OD, FAAO has been a cornerstone of the ICO community. Now serving as Chief of Innovative Technology and Data Science, he’s leading the institution into a new era of digital discovery. From pioneering research in glaucoma to exploring the power of artificial intelligence in clinical care, Dr. Chaglasian bridges traditional optometric practice with the technologies shaping its future. A founding figure in advancing glaucoma education nationwide, his leadership continues to inspire both faculty and students.

In this Faculty Spotlight, we take a closer look at Dr. Chaglasian’s journey: from his early days as a SUNY–trained clinician, to his current work with AI–powered diagnostic tools that could transform the future of optometry.

You’ve recently taken on the role of Chief of Innovative Technology and Data Science at ICO. How does this position build upon your past work in glaucoma research?

My new role reflects both the continuity and the evolution of my career at ICO. I’ve been here for about 30 years, primarily focused on glaucoma care, research, and education. Now, as Chief of Innovative Technology and Data Science, I’m exploring how artificial intelligence and digital tools can elevate clinical decision–making and patient outcomes, particularly within glaucoma management.

AI in health care can feel intimidating to some, but I see it as an opportunity. The goal isn’t to replace clinicians, it’s to empower them. At ICO, we’re in the early stages of building and validating AI algorithms that can assist doctors in interpreting patient data more effectively. For example, glaucoma diagnosis relies on the synthesis of multiple datasets, from visual fields to OCT scans to intraocular pressure readings, and AI has the potential to analyze those variables collectively, identifying subtle trends that even trained eyes might miss.

Of course, glaucoma remains my primary focus. It’s a disease that demands early detection, and optometry is uniquely positioned to make that possible. By integrating AI into routine eye care, we can move from reactive to proactive management by detecting subtle nerve fiber changes or pressure trends before vision loss occurs. That’s the promise that drives me today: equipping the next generation of optometrists with tools that not only enhance their clinical confidence but also expand what’s possible for patient care. 

Beyond your research, you’ve been instrumental in advancing glaucoma education both on and off campus. What continues to motivate your involvement in that mission?

Glaucoma is often called the “silent thief of sight,” and that phrase captures the urgency of why education is so critical. When I started at ICO, I quickly realized that there wasn’t a dedicated forum within optometry focused exclusively on this disease. Along with several colleagues, I helped establish the Optometric Glaucoma Society (OGS) more than 20 years ago. Today, as its Executive Director, I’m proud to see it flourish into an organization that brings together over 150 clinicians, educators, and researchers.

Our mission is simple but profound: to advance the teaching, research, and clinical management of glaucoma within optometry. Every year, we hold a national meeting, just before the American Academy of Optometry’s annual conference, where leaders share the latest research and innovations. It’s an invaluable opportunity for doctors to stay at the forefront of evolving treatments, from new medications to laser procedures such as selective laser trabeculoplasty (SLT), which is increasingly considered a first–line therapy.

The field itself is moving rapidly. For decades, glaucoma care revolved around topical medications. Now, we’re seeing a shift toward laser–based and minimally invasive surgical options that offer better compliance and fewer side effects. But all of these advances hinge on one thing: early and accurate diagnosis. That’s where optometrists come in. As primary eye care providers, they are on the front line of detection, and it’s essential they have both the knowledge and the confidence to make those calls.

At ICO, I see that same spirit of advancement reflected in our students and faculty. We’ve significantly expanded opportunities for student research, giving future clinicians hands–on experience in data analysis, experimental design, and evidence–based care; I believe this kind of training is what transforms a student into a lifelong learner. My advice to graduates is always the same: keep learning, attend conferences, and stay connected to professional organizations. The field is evolving too quickly to stand still.

After three and a half decades here, ICO feels like home. I didn’t graduate from this institution, but its mission and its people have shaped my career. This collaborative environment we’ve built, where research, teaching, and patient care intersect, is something truly special. I’ve stayed all these years because I love this work, I love this community, and I believe the best innovations in optometry are still ahead of us.